source
- Scholar Rock removes Novo Nordisk's Catalent plant from FDA filing for SMA drug apitegromabScholar Rock announced it will no longer list Novo Nordisk’s legacy Catalent facility as a contract manufacturer in its FDA resubmission for apitegromab, its spinal muscular atrophy (SMA) candidate…
- Safety concerns emerge as radiopharmaceuticals advance in cancer trialsRadiopharmaceuticals are being hailed for their ability to deliver radiation directly to tumours, potentially sparing surrounding healthy tissue and improving cancer therapy. However, as more cand…